Keryx Biopharmaceuticals Inc. (KERX) Upgraded to “Strong-Buy” at Vetr Inc.
Vetr upgraded shares of Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) from a buy rating to a strong-buy rating in a research report released on Wednesday. Vetr currently has $5.93 price target on the biopharmaceutical company’s stock.
Other research analysts have also recently issued research reports about the company. Ladenburg Thalmann boosted their price target on Keryx Biopharmaceuticals from $9.00 to $10.00 and gave the stock a buy rating in a research note on Tuesday, August 2nd. Stifel Nicolaus cut Keryx Biopharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, August 2nd. Maxim Group reiterated a buy rating and issued a $9.00 price target (up previously from $7.00) on shares of Keryx Biopharmaceuticals in a research note on Friday, July 8th. JMP Securities reiterated an outperform rating on shares of Keryx Biopharmaceuticals in a research note on Thursday, September 8th. Finally, Raymond James Financial Inc. boosted their price target on Keryx Biopharmaceuticals from $7.00 to $10.00 and gave the stock an outperform rating in a research note on Tuesday, August 2nd. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Keryx Biopharmaceuticals presently has an average rating of Hold and an average price target of $8.44.
Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) opened at 4.93 on Wednesday. The firm’s 50-day moving average price is $4.84 and its 200-day moving average price is $5.46. The firm’s market capitalization is $522.06 million. Keryx Biopharmaceuticals has a 52-week low of $2.80 and a 52-week high of $7.80.
Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its quarterly earnings data on Monday, August 1st. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.28) by $0.14. The company had revenue of $9.30 million for the quarter, compared to analyst estimates of $8.60 million. Keryx Biopharmaceuticals had a negative return on equity of 172.04% and a negative net margin of 590.50%. The company’s revenue for the quarter was up 272.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.26) EPS. On average, equities analysts predict that Keryx Biopharmaceuticals will post ($1.24) earnings per share for the current fiscal year.
In other news, CFO Scott A. Holmes sold 4,935 shares of the company’s stock in a transaction that occurred on Friday, July 29th. The stock was sold at an average price of $7.36, for a total transaction of $36,321.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 3.08% of the company’s stock.
Several institutional investors have recently bought and sold shares of the stock. Alpine Partners VI LLC bought a new position in Keryx Biopharmaceuticals during the second quarter valued at approximately $110,000. Trexquant Investment LP bought a new position in Keryx Biopharmaceuticals during the second quarter valued at approximately $115,000. Cambridge Investment Research Advisors Inc. raised its position in Keryx Biopharmaceuticals by 38.2% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 18,100 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 5,000 shares during the period. LMR Partners LLP bought a new position in Keryx Biopharmaceuticals during the second quarter valued at approximately $125,000. Finally, Stifel Financial Corp acquired a new position in shares of Keryx Biopharmaceuticals during the second quarter valued at about $170,000. 61.13% of the stock is owned by institutional investors.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis.
Receive News & Stock Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related stocks with our FREE daily email newsletter.